1 min readSanger Institute Acquires 11 More Illumina Genome Analyzers
San Diego, CA – Illumina has announced that the Wellcome Trust Sanger Institute has purchased 11 additional Genome Analyzers, increasing the organization’s total number of the Illumina sequencing platform to 37.
According to the announcement, the continued scale up on the Genome Analyzer will support the Sanger Institute’s many initiatives, such as its contribution to the 1000 Genome Project, which requires economical, accurate, and rapid sequence generation.
“The Sanger Institute has an important international role in producing and analysing genomic data. That role is founded in DNA sequencing and we will meet new challenges by investing in appropriate new technologies,” said Professor Julian Parkhill, Director of Sequencing at the Wellcome Trust Sanger Institute. “We are expanding our ability to contribute to major projects on human and mouse genome resequencing, pathogen genomics and genetics, and cancer genetics and to carry out our own research programmes within the Institute strategy.”